Joint venture between Isis Pharmaceuticals and Elan to develop an oral formulation of an antisense inhibitor of TNF-alpha for the treatment of rheumatoid arthritis. Elan's participation ended in 2002.

History:

Employment

Email:

Fax:

Mail:

General Info:

Ticker:

Employees:

Regions:
Southern California

Research Focus:
Disease Therapeutics-Clinical early (I, II)

 

Profiles:

 

News:

Keywords: 

Strategic Partnerships: